Press release
KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD
Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect Corium Continues Commercialization
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect Corium Continues Commercialization Effort in U.S. CELEBRATION, Fla., Nov. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS® will be featured in a poster presentation during the 2021 Virtual International Conference on ADHD, co-hosted by Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) with the ADHD Coaches Organization (ACO), and the Attention Deficit Disorder Association (ADDA), taking place November 4-6, 2021. The poster, titled, “Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study,” detailed a multicenter, pivotal study that assessed the efficacy and safety of AZSTARYS in 150 children aged 6 to 12 years with a diagnosis of ADHD. Results indicated that the trial’s primary endpoint was met, demonstrating significantly greater improvements from baseline on the Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale (SKAMP) scale in subjects treated with AZSTARYS versus a placebo (p","length":1906,"tagName":"div"}]